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Abstract
Transcriptome-wide studies of translation efficiencies are required to improve
understanding of translational regulation and its role in homeostatic mechanisms.
In Study 1, we developed an algorithm for analysis of translation efficiency, called
anota2seq. We show that anota2seq outperforms current methodologies and, due
to its unique analytical approach, it is the only method to statistically distinguish
important modes for regulation of gene expression, i.e translation and translational
buffering.
Pancreatic cancer is a lethal malignancy with very limited treatment options. In
Study 2, we evaluate the impact of using an eIF4A inhibitor, CR-31, on mRNA
translation in pancreatic cancer. eIF4A is a component of the eIF4F translation
initiation complex. We show that inhibiting eIF4A in murine and human pancreatic
ductal adenocarcinoma (PDAC) models induces an energy crisis by impacting
translation of mRNAs related to oxidative phosphorylation and glycolysis. This
leads to the shift of metabolic dependency of PDACs towards reductive glutamine
metabolism. Exploiting the dependence on reductive glutamine metabolism using
a combined treatment of eIF4A and glutaminase inhibitors revealed an exciting
therapeutic treatment strategy for PDAC that did not affect healthy cells.
In Study 3, we investigated the effects of insulin on gene expression in malignant
and non-malignant cells. This revealed that malignant cells modulate total mRNA
levels differently in response to insulin compared to non-malignant cells, whereas
in both translation was dependent on mammalian/mechanistic target of rapamycin
(mTOR). However, mTOR inhibition during insulin stimulation in malignant cells
lead to translational offsetting of alterations in total mRNA levels. Comparing
the effects of mTOR inhibition in malignant cells to that of hypoxia in stem cells
revealed that these vastly different cell types share the ability to translationally
offset mRNAs.
Collectively, these studies improved analysis of translational efficiencies and
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Figure 1.1: The gene expression pathway - DNA is transcribed into
RNA. RNAs are processed into mRNAs that consist of a 5’ cap,
exons and a poly(A) tail. mRNAs can be transported out of the
cellular nucleus into the cytoplasm where they can be degraded,
stored, or translated into proteins depending on cellular demands.
Synthesised proteins can be degraded by proteosomes. Coloured
boxes in the DNA refer to introns (teal) and exons (purple). Introns
are non-coding parts of the genome, whereas exons encoding regions.
mRNAs are depicted as purple lines, i.e. a series of exons, with an
AAAAA extension and an oval shape at its start. Proteins are
depicted as a series of pink balls.
1.1.1. The central dogma
of gene expression In
eukaryotic cells, genetic code
is stored as deoxyribonucleic
acid (DNA) molecules in the
nucleus. Transcription is the
process whereby temporary
copies of the DNA are
generated and occurs in the
nucleus. These copies are
called ribonucleic acid (RNA).
RNAs undergo processing
by which multiple different
variants coming from the same
gene are produced. A subset
of protein-encoding processed
RNAs is the so called
messenger RNA (mRNA).
mRNAs are transported from
the nucleus into the cytoplasm
where they can be stored,
degraded, or translated into
proteins. Proteins themselves can also be degraded (see figure 1.1). This flow
of genetic information into expressed proteins is commonly referred to as the
central dogma in molecular biology (F. Crick, 1970).
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1.1.2. Contribution to gene expression Proteins are the last product of the
gene expression pathway and carry out the vast majority of all cellular functions.
While it is apparent that modulation of protein levels will offer information on the
changes in gene expression, it cannot completely answer the question as to why
the protein levels change. In a disease context, protein levels alone might only
offer sufficient insight to explain phenotypic differences. Studying the mechanisms
that drive differences in protein levels is thus required to improve understanding
of biological processes and their dysregulation in disease.
Recently developed system biology methods allow investigation of gene expression
at multiple levels on a genome-wide scale. Initially, transcriptomics studies were
applied to study gene expression with the assumption that mRNA expression
is the main determinant for protein levels and therefore changes in transcript
abundance may be used as a proxy for alterations in the proteome. However, this
view was challenged by several landmark studies that observed a poor mRNA to
protein correlation and indicated a larger role of post-transcriptional regulation
in gene expression than previously assumed (Lu et al., 2005; Schwanhäusser et al.,
2011; Silva et al., 2016; Sousa Abreu et al., 2009; Vogel et al., 2012).
The debate regarding which step of the gene expression pathway contributes most
to the composition of the proteome is ongoing, nevertheless an understanding has
been reached that the context under which studies are carried out is a major
determinant. At steady state, mRNA levels seem to explain protein abundance
best, however in perturbed systems (e.g. under stress or growth factor signalling)
the contribution of transcript abundance appears to have less impact relative
to post-transcriptional steps in regulation of gene expression (Liu et al., 2016).
Moreover, it appears that correlation between mRNA and protein levels also
depends on the type of the stimulus. For example, in a study that stimulated bone
marrow-derived dendritic cells with LPS, protein levels were dependent on cellular
transcript levels (Jovanovic et al., 2015). In contrast, a study investigating cells
under endoplasmatic reticulum stress observed extensive modulation of protein
levels, whereas mRNA abundance was only mildly affected (Cheng et al., 2016).
Thus, the contribution of different steps of the gene expression pathway
is dependent on many different factors, e.g. cellular state or treatments.
Nevertheless, mRNA translation is an essential process in determining
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composition of the proteome. Furthermore, dysregulation of mRNA translation
has been observed in multiple diseases, ranging from neurological disorders to
cancer which warrants for a comprehensive understanding of this process (Graff
et al., 2009; Kapur et al., 2018; L. J. Lee et al., 2021; Ruggero, 2013; Tahmasebi
et al., 2018). This thesis focusses on increasing understanding of the role of
mRNA translation in cancer.
1.2. mRNA translation
1.2.1. Schematic representation of mRNA mRNAs contain a protein
coding region which is flanked by untranslated regions (5’ and 3’ UTRs). UTRs
contain post-transcriptional regulatory elements that may affect localisation,
stability and translation of the mRNA (Leppek et al., 2018; Loya et al., 2008;










5' UTR 3' UTR
Figure 1.2: Schematic overview of mRNA - mRNA consists of a coding sequence, 5’ and 3’ untranslated regions
flanking the coding sequence, a 5’ cap and a poly-(A)-tail. Located within the 5’ and 3’ untranslated region
are post-transcriptional regulatory elements that can influence gene expression. uORF; upstream open reading
frame; IRES, internal ribosome entry site; CPE, cytoplasmic polyadenylation site; AAUAAA, polyadenylation
signal. See section 1.3 for details on these elements.
The 5’ end of mRNAs contain a 7-methyl-guanylate (m7G) cap that is important
for translation initiation, while the 3’ end has a poly-A tail protecting the mRNA
against degradation (Grifo et al., 1983; Wilusz et al., 2001). Multiple different
mRNA variants (also called isoforms) from the same gene can exist. Isoforms
may arise due to alternative transcription start site usage or a process called
alternative splicing. Isoforms can co-exist at the same time and have differing
properties that can perform distinct functions (Joly Anne-Laure et al., 2018).
Furthermore, alternative splicing may result in isoforms with different 5’ UTRs.
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This leads to altered translation of mRNAs encoding for the same protein (Floor
et al., 2016; Jewer et al., 2020).
1.2.2. The steps of mRNA translation In eukaryotes, mRNA translation
occurs in the cytoplasm for the vast majority of protein coding mRNAs. However,
a small subset of mRNAs encoded by mitochondrial DNA is translated in the
mitochondria (D’Souza et al., 2018). mRNA translation is a process that consists
of several steps: initiation, elongation, termination and ribosome recycling (see













Figure 1.3: mRNA translation initiation, elongation, termination and ribosome recycling steps - The ribosome
binds to the mRNA and initiates scanning for a start codon (AUG). The elongation phase incorporates amino
acids into a polypeptide chain (i.e. the protein product). Once a stop codon (e.g. UGA) is detected, the
ribosome terminates translation and releases the polypeptide chain. The ribosome can then be recycled to
participate in the translation of another mRNA or reinitiate on the same mRNA. Green ovals represent the
ribosomal subunits. Within the ribosome the E, P and A-sites are indicated with yellow boxes (see section
1.2.2.2 for details). Polypeptide chains are depicted as a series of pink balls. Orange crosses represent transfer
RNAs (tRNA) (see section 1.2.2.2 and 1.3.3 for more details on tRNAs).
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1.2.2.1. Initiation In eukaryotes, 5’ cap-dependent initiation of mRNA
translation consists of multiple stages. First, a ternary complex (TC) consisting
of guanosine-tri-phosphate (GTP) bound eukaryotic initiation factor (eIF) 2 and
methionine-initiator transfer RNA (met-tRNAi) is formed. This is followed by
formation of the 43S pre-initiation complex (PIC). The PIC consists of a 40S
ribosome subunit, the TC and, translation initiation factors eIF1, eIF1A, eIF3
and, eIF5 (Asano et al., 2000). mRNAs then undergo “activation.” Here, the 5’
cap proximal structure is bound by eIF4F. eIF4F is the 5’ cap binding complex
consisting of: the 5’ cap binding protein eIF4E, the RNA helicase eIF4A and,
a scaffold protein eIF4G (Grifo et al., 1983). The Poly (A) binding protein
(PABP) binds to the poly(A) tail of the 3’ UTR and causes circularisation of
the mRNA. The circularisation improves stability of the mRNA and aids in
recruitment of translation initiation factors (Ivanov et al., 2016). Upon mRNA
recruitment, the ATP-dependent eIF4A helicase activity of the eIF4F complex
facilitates scanning of 43S PIC along the 5’UTR together with eIF4B and
eIF4H. Recognition of the translation initiation codon (AUG) induces formation
of the 48S initiation complex. Once the initiation codon (AUGi) is reached,
displacement of eIF1 occurs which allows eIF5 to hydrolyse eIF2-bound GTP.
The 60S ribosomal subunit then joins the 40S ribosomal subunit which causes
the release of eIF2-GDP and other initiation factors (eIF1, eIF3, eIF4B, eIF4F
and eIF5). Subunit joining is mediated by eIF5B. After subunit joining the 80S
ribosome is formed and the elongation process starts (see figure 1.2.2.1) (Asano et
al., 2000; Alan G. Hinnebusch, 2006; Jackson et al., 2010). A mechanism for cap
dependent translation initiation that is independent of eIF4E has been described.
Here, eIF3d binds the 5’ cap of mRNAs containing an RNA element that blocks
eIF4E binding A. S. Y. Lee et al. (2016). Next to 5’cap-dependent initiation,
mRNA translation can also be initiated in a 5’ cap-independent manner, e.g. via
the internal ribosome entry site (IRES) (see figure 1.2). Mechanisms for 5’
cap-independent mRNA translation initiation are extensively reviewed elsewhere
(Lacerda et al., 2017; Shatsky et al., 2018).
1.2.2.2. Elongation The 80S ribosome contains three sites important for
decoding an mRNA: the aminoacyl (A), peptidyl (P) and exit (E) sites. During
elongation in eukaryotes, aminoacytelated tRNAs are delivered to the A-site
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in a ternary complex with eukaryotic elongation factor (eEF) 1A and GTP. If
the tRNA is cognate to the codon in the A-site of the ribosome, GTP bound
to eEF1A is hydrolysed. This causes eEF1A to release and accommodates the
aminoacetylated tRNA in the A-site. This is followed by a peptidyl transferase
reaction. This reaction forms the peptide bond between the peptidyl tRNA in
the P-site and amino group of the aminoacyl-tRNA in the A-site (aa-tRNA)
and is catalysed by 60S ribosomal subunit. After the peptide bond is formed a
translocation step occurs through eEF2-GTP hydrolysis. The translocation step
encompasses that the deacetylated tRNA currently in the P-site moves into the
E-site. Likewise, the peptidyl tRNA in the A-site moves to the P-site. Which
leaves the A-site open for other aa-tRNAs. The deacytelated tRNA in the E-site
is then released from the ribosome (Dever et al., 2012). This process is repeated
until a stop codon (UAA, UGA or UAG) enters the A-site of the ribosome.
6
Figure 1.4: Pathway of eukaryotic translation initiation via ribosomal scanning. Reprinted with permission.
Cold Spring Harb Perspect Biol. 2012 Oct; 4(10): a011544.doi: 10.1101/cshperspect.a011544.© 2012 Cold Spring
Harbor Laboratory Press.
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Figure 1.5: Electromicrongraph of ribosomes
extracted from different positions along
a sucrose gradient used for polysome
fractionation (A-C). Multiple ribosomes
bound to the same mRNA can be observed.
For details on polysome fractionation see
section 1.4. Reprinted with permission.
DR. T. STAEHELIN et. al. Nature.1963
Aug 31;199:865-70.doi: 10.1038/199865a0.
Copyright © 1963, Nature Publishing Group.
1.2.2.3. Termination and recycling
mRNA translation termination is facilitated
by two eukaryotic release factors (eRF),
eRF1 and eRF3-GTP (Alkalaeva et al., 2006;
Stansfield et al., 1995). The eRF1:eRF3-GTP
complex binds to the A-site of the ribosome
upon recognition of a stop codon. This
causes an hydrolysis event resulting in a
conformational change and release of the
polypeptide chain. eRF1 and the ATP binding
cassette protein (ABCE1) together promote
the splitting of the 60S and 40S subunits
after which they can be recycled (Hellen, 2018;
Pisarev et al., 2010).
1.2.3. Translation efficiency Each
ribosome synthesises a single protein during
translation of an mRNA assuming it is not
prematurely terminated. It has been known
since the ‘60s that translation of an mRNA
occurs via multiple bound ribosomes (polysomes) simultaneously (see figure
1.5A-C) (Staehelin et al., 1963; Warner et al., 1962). Therefore, the translation
efficiency of an mRNA depends on the number of ribosomes it is associated with.
Experimental methods like polysome profiling and ribosome profiling are used
to study translation efficiency by measuring the number of ribosomes bound on
an mRNA (explained in detail in section 1.4). While all steps of translation can
affect the translation efficiency of an mRNA, it is thought to most commonly be
regulated at the initiation step (Dever et al., 2012; Jackson et al., 2010; Richter
et al., 2015). This is supported by findings using polysome profiling in yeast
that was cultured in nutrient rich medium where initiation was rate-limiting
for most mRNAs (Arava et al., 2003). Furthermore, a recent ribosome profiling
study assessed transcriptome-wide elongation rates. This revealed a similar rate
of elongation for mRNAs of different classes, e.g. mRNAs with differences in 5’
UTR characteristics (Ingolia et al., 2011). The next section will go further into
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detail how translation initiation and elongation can be regulated.
1.3. Regulation of mRNA translation
mRNA translation is the most energy consuming process in the cell. In a study
using concanavalin A stimulated rat thymocytes, it was estimated that translation
accounts for ~20% of the cellular energy consumption (Buttgereit et al., 1995).
The high energy consumption of mRNA translation and its central role in the
gene expression pathway requires it to be tightly regulated.
Regulation of translation can be exerted at a global level, i.e. regulation of a large
set of mRNA simultaneously. Global regulation of mRNA translation can be
achieved by, e.g. perturbations of major signalling pathways impinging on mRNA
translation. Regulation of mRNA translation is that it can affect specific mRNA
populations selectively. Selective translational regulation acts on characteristics
of mRNAs, e.g. through 5’ UTRs or RNA binding proteins (RBP) that bind to
the 3’ UTRs (see figure 1.2) (Leppek et al., 2018). Furthermore, regulation
of initiation factors can also regulate translation selectively Gandin, Masvidal,
Hulea, et al. (2016). Below we will discuss multiple mechanisms that regulate
mRNA translation globally or selectively.
1.3.1. mTOR mTOR is a conserved Ser/Thr kinase and is found in two
structurally and functionally distinct complexes, mTORC1 and mTORC2 (Pearce
et al., 2007; Saxton et al., 2017). In a growth promoting environment mTOR
regulates cell metabolism to increase protein synthesis, lipids and nucleotides,
while suppressing catabolic pathways, e.g. autophagy. mTORC2 promotes
survival via signalling through protein kinase A (AKT), anabolic metabolism,
and cytoskeleton regulation Zoncu et al. (2011).
mTORC1 activity is modulated via hormone and growth factor signalling,
e.g. insulin and insulin-like growth factor (IGF1). This signalling is predominantly
mediated through the phosphoinositide 3-kinase (PI3K) / AKT pathway.
PI3K activation generates phosphatidylinositol-3,4,5-trisphosphate (PIP3).
Phosphatase and tensin homologue (PTEN) can counteract this by hydrolysis
of PIP3 to phosphatidylinositol 4,5-bisphosphate (PIP2). PIP3 recruits
phosphoinositide-dependent kinase 1 (PDK1) and AKT to the plasma membrane.
At the plasma membrane AKT is activated through phosphorylation of PDK1.
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AKT in turn increases activity towards its substrate tuberous sclerosis complex
(TSC). TSC consists of a scaffold protein, TSC1, and a GTPase, TSC2.
TSC negatively regulates mTORC1 activity. This negative regulation occurs
through hydrolysis of Ras homologue enriched in brain (Rheb) that leads to
its inactivation. Rheb binds to mTOR to promote its activity (see Figure 1.6).
Furthermore, several cross-talk mechanism with other pathways (e.g. RAS/ERK)
have been shown to lead to mTORC1 activation (reviewed in (Reuben J. Shaw
et al., 2006)). The mechanisms of mTORC2 activation are less well understood.
The PI3K pathway is involved in oncogenic signalling and under investigation as
therapeutic target in cancer (Hilger et al., 2002; Yang et al., 2019). In several
cancers (e.g. breast, lung, prostate and colon) the gene encoding the catalytic
p110𝛼 subunit of PI3K (PI3KCA) is frequently mutated or amplified (J. W. Lee
et al., 2005; D. A. Levine et al., 2005; Samuels et al., 2004). The E545K mutation
leads to a reduced inhibitory effect of the regulatory p85 subunit on PI3KCA. In
study 3, we investigate oncogenic signalling via the PI3K pathway activated by
insulin. Here, were focus on the role of mTOR in mediating the effects of insulin
on gene expression in the MCF7 breast cancer cell line that harbours the E545K
mutation (Schneck et al., 2013). Hyperactivity of PI3K/AKT signalling has been
reported in multiple cancers and has been linked to anti-cancer therapy resistance
(Pópulo et al., 2012; Salaroglio et al., 2019; Tan et al., 2013). Furthermore, both
PTEN and the TSC act as tumour suppressors and are frequently mutated in
cancer (Mak et al., 2004; Song et al., 2012). Therefore, mTOR has become a
focus of anti-cancer therapy by either targeting mTORC1 or using dual inhibitors
for PI3K and mTOR (Bhat et al., 2015).
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Figure 1.6: Schematic representation of mTOR signalling to the translational machinery. Philippe P. Roux, and
Ivan Topisirovic Mol. Cell. Biol. 2018; doi:10.1128/MCB.00070-18. Reprinted with permission. Copyright ©
2018, American Society for Microbiology
mTOR also fulfills a central role in metabolic signalling. Here, mTOR
integrates signals arising through amino acid availability, glucose metabolism
and cellular oxygen levels. For example, increased amino acid availability
induces relocalisation of mTOR into proximity of Rag GTPases leading to its
activation through Rheb (Sancak et al., 2008). Furthermore, Glucose deprivation
leads to increased adenosine-mono-phosphate kinase (AMPK) signalling via
serine/threonine kinase 11 (LKB1) (Kimball, 2006; Sanders et al., 2007; R. J.
Shaw, 2009). In turn, AMPK phosphorylates TSC2 leading to its activation
(Kimball, 2006). LKB1 mutations have been found in cancer and are being
considered as targets in anti-cancer therapy (Zhao et al., 2014). Hypoxia also
inhibits mTOR via regulated in development and DNA damage response 1
(REDD1) which stabilises the TSC (Brugarolas et al., 2004). While hypoxia
(i.e. deprivation of oxygen) inhibits protein synthesis in normal cells, in breast
cancer, protein synthesis appeared not to be significantly inhibited during
11
hypoxia which is attributed to uncontrolled mTOR signalling (Connolly et al.,
2006).
In cancer, cellular metabolism, proliferation as well as growth are often
dysregulated (Hanahan et al., 2011). Given the central of mTOR governing
proliferation, growth, and metabolism it is vital to comprehensively understand
mTOR signalling in this disease (Roux et al., 2018).
1.3.1.1. Global regulation of translation via mTOR Well studied
downstream targets of mTOR for the regulation of mRNA translation are
4E-binding proteins (4E-BP) and ribosomal protein S6 kinases (S6Ks). mTOR
phosphorylates 4E-BP leading to the release of eIF4E that then can engage in
eIF4F complex formation (Gingras et al., 1999). Therefore, inhibition of mTOR
leads to a down regulation of 5’ cap-dependent mRNA translation.
S6Ks have been shown to regulate phosphorylation of multiple components of the
translation machinery, e.g. ribosomal protein S6 (rpS6), programmed cell death
protein 4 (PDCD4), eEF2 kinase and eIF4B. S6K phosphorylates rpS6 which
has been implicated in the regulation of cellular growth and protein synthesis
(Ruvinsky et al., 2005). Furthermore, S6K/rpS6 signalling was suggested to
be involved in ribosome biogenesis. Another S6K target is eEF2 kinase which
phosphorylates and inhibits eEF2, thus attenuating elongation rates. (X. Wang
et al., 2001). MTORC1 phosphorylates and inhibits eEF2K either directly
or via S6Ks. Furthermore, phosphorylation of PDCD4 by S6K triggers its
degradation. PDCD4 blocks eIF4G-eIF4A interactions repressing eIF4A activity
and cap-dependent mRNA translation (Dorrello et al., 2006; Göke et al., 2002).
Lastly, phosphorylation of eIF4B by S6K is suggested to stimulate the unwinding
activity of eIF4A (Rogers et al., 2001).
Collectively, through acting on its downstream targets, mTOR regulates
translation globally via a number of mechanisms.
1.3.1.2. Selective or ”mTOR sensitive” regulation of translation
1.3.1.2.1. Terminal oligo pyrmidine mRNAs Selective or “mTOR
sensitive” regulation of translation can act on a terminal oligo pyrimidine (TOP)
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motif in the 5’ UTR of mRNAs. This TOP motif consists of a C followed
by a stretch of 4-15 pyrimidines directly after the 5’ cap. TOP mRNAs show
near complete dissociation from ribosomes under conditions when mTOR is
inhibited and are enriched for genes encoding for components of the translation
machinery (Meyuhas, 2000; Thoreen et al., 2012; Yamashita et al., 2008). Recent
works indicate the importance of La ribonucleoprotein domain family member 1
(LARP1) in regulation of TOP mRNAs with contradictory findings (Fonseca et
al., 2015; Hopkins et al., 2016; Jia et al., 2021; Maraia et al., 2017). A panel of
researches was asked to evaluate these findings, which led to the establishment of
a model for translational regulation via LARP1 (Berman et al., 2021). According
to this model, LARP1 binds to the 5’ mRNA cap of TOP mRNAs via its DM15
domain. Binding of DM15 represses translation of TOP mRNAs by obstructing
eIF4E binding and occurs in instances where mTOR activity is reduced. Under
conditions where mTOR is active, DM15 is phosphorylated by mTOR. This
causes DM15 to release the 5’ cap. However, the la domain of LARP1 remains
bound to the 3’ UTR. The still bound la domain stabilises the mRNA to facilitate
translation (Berman et al., 2021). Other instances of selective translation by
mTOR are explained in the next section.
1.3.1.2.2. Selective regulation through members of the eIF4F complex
As mentioned above, the eIF4F complex consists of eIF4E, eIF4A and eIF4G and
is required for cap-dependent mRNA translation (Alan G. Hinnebusch, 2014).
The availability of the eIF4F complex is limited under basal conditions due to
that eIF4E is bound by 4E-BPs. Therefore, under basal conditions mRNAs
must compete for access to components of the translation machinery. Such
competition is affected by characteristics of 5’ UTRs that introduce variation
to how well mRNAs can be translated. Benedetti et. al. derived and expanded on
a model for mRNA competition originally proposed by Lodish (De Benedetti et
al., 2004 ; Lodish, 1974). Herein, “strong” mRNAs are widely expressed and,
represent the majority of cellular mRNAs and are characterised by optimally
long and unstructured 5’ UTRs, e.g. 𝛽-actin. An optimal 5’ UTR length of
70-150 nucleotides was proposed by Kozak (Kozak, 1987). On the other hand,
“weak” mRNAs have long and structured 5’ UTRs. “Weak” mRNAs encode for
potent growth and survival factors, e.g. c-Myc, ornithine decarboxylase (ODC1)
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and vascular endothelial growth factor (VEGF). Translation of “strong” mRNAs
would remain effective in conditions where eIF4F complex availability would be
limited. However, “weak” mRNAs show sensitivity to eIF4F availability which is
dependent on eIF4E expression and/or availability (Graff et al., 2008). Elevated
eIF4E expression and/or availability due to increased mTORC1 activity and
consequent inhibition of 4E-BPs are common in cancer and drives malignancy due
to selective induction of translation of tumour promoting mRNAs (De Benedetti
et al., 2004).
In addition to eIF4E, other eIF4F subunits have been shown to also selectively
impact mRNA translation. Therein, mRNAs dependent on eIF4A showed
characteristics of “weak” mRNAs, i.e. these mRNAs had long and structured
5’ UTRs (Rubio et al., 2014; Waldron et al., 2018; Wolfe et al., 2014).
Structural elements in the 5’ UTRs include classical hairpins formed through
Watson-Crick base pairing (see Figure 1.2) (Leppek et al., 2018). Other structures
formed via hoogsteen base pairing have also been proposed to regulate eIF4A
dependent mRNA translation (Wolfe et al., 2014). These structures are called
G-quadruplexes. G-quadruplexes are stable structures formed by stacking two or
more G-tetrads (Kwok et al., 2017). However, whether G-quadruplexes form in
RNA is still debated (Biffi et al., 2014; Guo et al., 2016; Laguerre et al., 2015;
Weldon et al., 2016). Formation of G-quadruplex structures is predicted based on
occurrences of 𝐺𝐺𝐶4 motif repeats in the 5’ UTR of mRNAs (Singh et al., 2021;
Wolfe et al., 2014). Indeed, multiple studies report enrichment of 𝐺𝐺𝐶4 motifs in
mRNAs whose translation is dependent on eIF4A (Modelska et al., 2015; Rubio et
al., 2014; Singh et al., 2021; Waldron et al., 2018). However, Waldron et al. show
that 𝐺𝐶𝐶4 motifs fail to form G-quadruplexes in their reporter mRNA system.
The authors concluded that eIF4A dependence of mRNAs with 𝐺𝐺𝐶4 motifs
enriched in their 5’ UTR was likely mediated by classical hairpin-like structures
(Waldron et al., 2018). In addition, in Rubio et al. one third of eIF4A-dependent
mRNAs exhibited multiple 5’ UTR variants, while for eIF4A-independent
mRNAs this was < 1% (Rubio et al., 2014). Translation of mRNAs with different
5’ UTR variants has recently been implicated to drive cancer cell plasticity
towards more “stem cell-like” phenotypes during hypoxia (Jewer et al., 2020).
In addition, eIF4A inhibitors with different mechanisms of action have been
shown to exert different impact on the translatome. Hippuristanol inhibits RNA
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interaction by selective binding to eIF4A (Bordeleau et al., 2006; Lindqvist et al.,
2008). In contrast rocaglates and their derivatives, e.g. silvestrol and CR-1-31-B,
clamp eIF4A on polypurine sequences on the mRNA (Iwasaki et al., 2016).
Recently, a more nuanced picture for translation of mRNAs sensitive to inhibition
of components of the eIF4F complex has been reported (Gandin, Masvidal, Hulea,
et al., 2016). Therein, a comparison of treatments with a mTOR and eIF4A
inhibitors was evaluated. This revealed that non-TOP mTOR-sensitive mRNAs
encompass two functionally distinct sets of mRNAs. These sets were characterised
by different 5’ UTR features. Here, one subset showed less sensitivity to eIF4A
but more so to eIF4E (here after referred to as mTOR-eIF4E sensitive mRNAs).
mTOR-eIF4E sensitive mRNAs contain very short 5’ UTRs (< 40 nt) and encode
for proteins in metabolic functions. The other subset was sensitive to both eIF4E
and eIF4A (hereafter referred to as mTOR-eIF4A sensitive). mTOR-eIF4A
sensitive mRNAs were characterised by long and structured 5’ UTRs that encode
for pro-survival proteins. The authors concluded that inhibition of mTOR-eIF4A
dependent programs would lead to cytotoxic effects. Whereas, inhibition of
mTOR-eIF4E mRNAs would lead to metabolic dormancy and a cytostatic
effect (Gandin, Masvidal, Hulea, et al., 2016). The difference in cytostatic and
cytotoxic effects was attributed to that eIF4A inhibition leads to continuous
expression of proteins involved in respiration. However, expression of proteins
protecting mitochondrial integrity would be reduced. Thus, leading to apoptosis.
In contrast, inhibition of mTOR activity would impact protein expression of
both subsets simultaneously, leading to metabolic dormancy.
1.3.2. The integrated stress response The integrated stress response (ISR)
is a pathway activated through kinases responding to various stress signals. These
kinases include: Protein kinase R-like endoplasmic reticulum kinase (PERK)
activated by misfolded peptides in the endoplasmatic reticulum (ER); Heme
regulated eIF2alpha kinase (HRI) activated during heme deficiency; Protein
kinase R (PKR) which is activated in response to certain viral infections by
binding to double-stranded RNA (dsRNA); and general control nonderepressible
2 (GCN2) which is activated when cells are deprived of amino acids (Dmitry E.
Andreev et al., 2015; Guan et al., 2017; Kapur et al., 2017; Lemaire et al., 2005;
Taniuchi et al., 2016).
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1.3.2.1. Global and selective regulation of translation via the ISR
Similar to mTOR signalling, regulation of translation via the ISR is achieved at a
global and selective level. During the ISR the 𝛼 subunit of eIF2 is phosphorylated.
Phosphorylated eIF2𝛼 directly engages the guanine nucleotide exchange factor
eIF2B and prevents conversion of inactive eIF2-GDP to active eIF2-GTP needed
for met-tRNAi incorporation in the TC. This reduces TC availability and causes
a global downregulation of mRNA translation (Sonenberg et al., 2009) (see figure
1.4). While global translation is reduced upon ISR, translation of a selective
subset of mRNA with upstream open reading frames (uORFs) is increased. A
uORF is a reading frame that originates in the 5’ UTR of an mRNA upstream
of the coding ORF (cdsORF) (see Figure 1.2). uORFs can be out of frame with
the cdsORF and, when translated, lower the expression of the cdsORF (Kozak,
1984). Activating transcription factor 4 (ATF4), that regulates expression of stress
response genes, contains multiple uORFs of which one partially overlaps with the
cdsORF. Under normal conditions ATF4 translation is initiated at uORF1 and
reinitiation at uORF2 occurs. The overlap of uORF2 with the cdsORF causes
ribosomes to synthesise protein from uORF2 thereby inhibiting the translation
of the cdsORF. Limitation of TC availability during ISR causes longer ribosome
scanning times leading to that ribosomes scan past uORF2 and initiate at the
cdsORF (i.e. delayed reinitiation) (Pakos-Zebrucka et al., 2016).
Ribosome profiling studies indicate that 50% of mammalian mRNAs harbour
uORFs (see section 1.4 for details on ribosome profiling). mRNAs containing
uORFs include oncogenes and transcripts important in differentiation and cell
cycle (Calvo et al., 2009; Ingolia et al., 2011). Apart from delayed reinitiation,
uORF translation can also be regulated by “leaky scanning.” The surrounding
sequence of the uORF is important for initiation of translation. An AUG in
the classical Kozak context (i.e. RNNAUGG) is most efficient for translation
initiation due to better recognition by the met-tRNAi (Calvo et al., 2009; Kozak,
1986). Unfavoured flanking sequences of the AUG can cause the ribosome to
scan past the AUG, this process is called “leaky scanning.” An example of this
is DNA-inducible gene 34 (GADD34) which increases its translation upon ER
stress, i.e. a condition where eIF2𝛼 is phosphorylated. In humans, GADD34
contains two uORFs separated by 30 nucleotides (Y.-Y. Lee et al., 2009). In
contrast to the uORFs in ATF4, the uORFs in GADD34 are too close together
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to allow for reinitiation. Under basal conditions uORF2, which has a poor Kozak
context, represses translation of the cdsORF. However, under stress causing eIF2𝛼
phosphorylation, ribosomes scan past uORF2 to translate the cdsORF (Young et
al., 2015). Lastly, structural elements in proximity of the uORF can also influence







































Figure 1.7: Schematic representations of (A) the tRNA cloverleaf
structure with indicated anti-codon and amino acid acceptor sites;
(B) the proliferation and differentiation mRNAs dependent on
distinct tRNA subsets; (C) the U34 wobble position and the




tRNAs As touched upon
earlier, tRNAs are an essential
part of the translation
machinery that carry the
amino acids to the ribosome.
In eukaryotes, tRNAs consist
of a 76-90 long nucleotide
sequence set into a “cloverleaf”
structure forming several
loops (Sharp et al., 1985) (see
figure 1.7). The acceptor stem
binds the amino, while the
anti-codon loop binds to the
mRNA within the ribosome
via classical Watson-Crick
base pairing (Watson et al.,
1953). Multiple codons can
encode for the same amino acid (synonymous codons), however the availability
of the tRNAs for different codons may vary which can influence elongation rates
and thus protein synthesis.
This supply ( i.e. tRNA availability) and demand (i.e. codon composition)
relationship has been found to vary across different cellular states, e.g. proliferation
and differentiation. Gingold et. al. observed two different tRNA subsets. One
subset is induced when proliferation is stimulated and is otherwise repressed.
And the other subset increases expression when differentiation is induced and
is repressed otherwise (see figure 1.7). Both tRNA subsets match the codon
17
demand of the transcriptome under their respective cellular state (Gingold et
al., 2014). This model has been disputed and it was proposed that the observed
differences may be attributed to GC content in the mRNA (Rudolph et al., 2016).
Nevertheless, aberrant tRNA expression and codon usage have been reported in
cancer (Z. Zhang et al., 2018). Furthermore, a comprehensive study using small
RNAseq (e.g. for identification of tRNAs) and protein samples across 17 tissues
reported a tRNA signature stratified by proliferation marker Ki67 staining. The
identified tRNA signature has implications for patient survival (Hernandez-Alias
et al., 2020). Therefore, while a consensus on proliferation specific tRNA subsets
might not have been reached, emerging evidence implicates a role thereof in
cancer (Gingold et al., 2014; Hernandez-Alias et al., 2020; Z. Zhang et al.,
2018). For instance, increased expression of 𝑡𝑅𝑁𝐴𝐴𝑟𝑔𝐶𝐶𝐺 and 𝑡𝑅𝑁𝐴𝐺𝑙𝑢𝑈𝑈𝐶 has
been observed in breast cancer cell lines and are proposed to drive metastasis
(Goodarzi et al., 2016).
Others reported of a role for tRNAs in cancer attributed to tRNA modifications,
specifically at the highly conserved U34 anti-codon (wobble) position (El Yacoubi
et al., 2012; Lorent et al., 2019; Rapino et al., 2017). The ability to wobble was
proposed by Francis Crick and refers to non-Watson-Crick base pairing of tRNA
anti-codons (F. H. Crick, 1966). This enables a smaller set of tRNAs (41-55
in eukaryotes) to encode for the 64 possible codon combinations (Goodenbour
et al., 2006). In mammals, the U34 modification catalytic cascade involves
the acetyltransferase Elongator (ELP3), the methyltransferase TRM9-like
domain of Alkylation repair homolog 8 (ALKBH8), and the urmylation (URM)
pathway. The URM pathway includes the cytosolic thiouridylase homolog 1 and
2 (CTU1/CTU2) (Kalhor et al., 2003; Karlsborn et al., 2014). These enzymes
ultimately modify the U34 position into 5-methoxycarbonyl-methyl-2-thiouridine
(𝑚𝑐𝑚5𝑠2𝑈) which ensures cognate codon recognition. This modification is
thought to occur in tRNAs with a U in the wobble position, e.g. 𝑡𝑅𝑁𝐴𝑈𝑈𝑈 ,
𝑡𝑅𝑁𝐴𝑈𝑈𝐶, 𝑡𝑅𝑁𝐴𝑈𝑈𝐺, 𝑡𝑅𝑁𝐴𝑈𝐶𝐶, and 𝑡𝑅𝑁𝐴𝑈𝐶𝑈 (see figure 1.7).
Loss of the ability to modify U34 has been shown to reduce translation elongation
rates with varying effects on protein expression (Deng et al., 2015; Nedialkova
et al., 2015; Zinshteyn et al., 2013). While in some cases U34 dependent
signalling led to ribosome stalling resulting in protein aggregates and increased
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stress (Nedialkova et al., 2015; Zinshteyn et al., 2013), others reported a subtle
downregulation of proteins encoded by mRNAs requiring U34-modified tRNAs
(Deng et al., 2015). U34 modification dependent tRNAs have been shown to
play a role in cancer. For example, ELP3 is important in tumour initiation in
intestinal epithelia and promotes breast cancer invasion as well as progression to
metastasis (Delaunay et al., 2016; Ladang et al., 2015).
1.3.4. RNA binding proteins and trans-acting factors The UTRs of an
mRNA contain sequence elements to which small RNA and RNA binding proteins
(RBPs) bind and exert translational regulation (see figure 1.2).
1.3.4.1. microRNAs microRNAs (miRNA) are a class of small non-coding
RNA. The precise role and mechanisms of regulation of translation by miRNAs
are still under active investigation (Oliveto et al., 2017). However, miRNAs can
directly bind to other mRNAs and silence them which is accomplished through
translational repression or destabilisation (Jonas et al., 2015). Regulation of gene
expression by miRNAs has been observed in cancer. Here, miRNAs have been
implicated to promote tumorigenesis or act as tumour suppressors (Muniyappa et
al., 2009; Nagpal et al., 2015; Sampson et al., 2007; Tian et al., 2010).
1.3.4.2. RNA binding proteins RBPs are a class of proteins involved in
many regulatory steps of gene expression and account for ~7.5% of the protein
coding genes. RBPs bind to elements in the 3’ UTRs, e.g. the poly (A) tail. One
RBP binding the poly(A) tail is PABP. As explained in section 1.2.2.1 PABP is
involved in mRNA translation initiation and stabilisation of the mRNA (Afonina
et al., 2014; Amrani et al., 2008) (see also figure 1.4).
Another site in the 3’ UTR is the U-rich cytoplasmic polyadenylation (CPE) site
to which cytoplasmic polyadenylation element binding proteins (CPEBs) can bind
(see Figure 1.2). Studies in Xenopus oocytes indicate that CPEB associates with
a non-canonical poly(A) polymerase (Gld2) and a poly(A) deadynelase (PARN).
PARN has a higher activity than Gld2 and thus binding of CPEB to an mRNA
leads to shortening of the Poly(A) tail (Barnard et al., 2004). However, hormonal
stimulation leading to CPEB phosphorylation removes PARN from the complex.
Removal of PARN promotes poly(A) tail elongation through Gld-2 (Kim et al.,
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2006). Furthermore, in Xenopus oocytes, CPEB associates with an eIF4E binding
protein, i.e. maskin. Maskin bound to eIF4E prevents eIF4F complex formation
which represses mRNA translation (Ivshina et al., 2014; Stebbins-Boaz et al.,
1999). Therefore, CPEBs can regulate translation by altering 3’ UTR lengths
and are involved in translational repression by blocking eIF4E association with
the 5’ cap in Xenopus oocytes. While the role of CPEB mediated regulation
has been described mostly in Xenopus oocytes, dysregulation of CPEBs has been
observed in glioblastoma, colorectal and pancreatic cancer (Chang et al., 2014;
Ortiz-Zapater et al., 2011; Villanueva et al., 2017).
Another important RBP implicated in regulation of translation is Human antigen
R (HuR). HuR preferentially binds to AU-rich sequences in the 3’ UTR, acts as
a stabilising agent and is involved in RNA-processing (Baou et al., 2011; Fan et
al., 1998; T. D. Levine et al., 1993; Peng et al., 1998). In colorectal carcinoma
cells HuR has been shown to enhance protein synthesis of p53 after exposure
to short-wavelength UV light (UVC) by binding the 3’ UTR (Mazan-Mamczarz
et al., 2003). The enhanced effect on protein synthesis was not mediated by
stability as HuR failed to stabilise p53 upon UVC exposure. In human bone
osteosarcoma epithelial cells, overexpression of HuR led to a dose dependent
increase in eIF4E protein levels. The increase in protein levels was atrributed to
eIF4E transcript stabilisation through binding of HuR to AU-rich elements (AREs)
in the 3’ UTR of eIF4E (Topisirovic et al., 2009). Other known drivers of tumor
progression targeted by HuR include hypoxia inducible factor 1 (HIF-1), VEGF,
c-Myc (Denkert et al., 2004; López de Silanes et al., 2003, 2005). Furthermore,
studies in breast, colon and lung cancer observed correlation between HuR and
malignancy (Denkert et al., 2004; López de Silanes et al., 2003, 2005).
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Polysome profiling Ribosome profiling
Separation of mRNAs based on
the number of bound ribosomes






Quantification, e.g. via RNA sequencing
Figure 1.8: Polysome profiling and ribosome profiling workflows.
In polysome profiling a fraction from whole cytoplasmic RNA is
loaded onto a sucrose gradient on which they get separated by
sedimentation into the sucrose gradient using ultra centrifugation.
Fractions corresponding to efficiently translated mRNAs are
collected and can be quantified with for example RNA sequencing
(left). During ribosome profiling a fraction from the whole
cytoplasmic RNA is exposed to a digestion agent which breaks the
RNA. Ribosomes will protect fragments thereby creating ribosome
protected fragments. These fragments are then isolated and can









profiling (see figure 1.8).
These methods capture
the number of ribosomes
an mRNA is associated
with. The number of bound
ribosomes is an adequate
of estimator changes in
translation efficiencies when
initiation is rate limiting.
Indeed, as explained above




for separation of polysomes
from monosomes, ribosomal
subunits and messenger ribonucleoprotein particles (mRNPs). During this assay,
ribosomes are immobilized on the mRNAs using translation elongation inhibitors,
e.g. cycloheximide (CHX). Cytoplasmic extracts sediment on a linear sucrose
gradient (5-50%) using ultra centrifugation. The resulting gradient is fractionated
and mRNAs with different numbers of bound ribosomes can be extracted and
analyzed for mRNA content (Gandin et al., 2014). Typically fractions belonging
to mRNAs with more than 3 bound ribosomes are pooled. A 3-ribosome cutoff
has been chosen as it is thought to capture most biologically relevant changes in
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Figure 1.9: Polysome profliles - (top left) Schematic representation
of a polysome profile using linear sucrose gradient fractionation.
Indicated in the polysome profiles are the 40S, 60S ribosomal
subunits as well as the 80S monosome. H.P. indicates heavy
polysome fractions. Between conditions (i.e. black an pink lines)
distribution changes for mRNA abundance (grey and green; top
right), translation (grey and red; bottom left) and translation within
high polysome fractions (grey and red; bottom right) are illustrated.
An illustration of a polysome
profile with peaks for the
40S, 60S subunits and 80S
ribosome can be seen in (Fig
1.9 top left). Subsequent peaks
along the fractions indicate
the mRNAs with 2 or more
bound ribosomes. mRNAs are
typically normally distributed
along the fractions, i.e. in
a pool of the same mRNA
many will be associated with
different numbers of ribosomes
(Gandin, Masvidal, Hulea, et
al., 2016). Changes in mRNA
abundance may lead to an
overall increase in the amount
of isolated polysome-associated mRNA without a shift of the distribution along
the fractions (Fig 1.9 top right). This means that the translation efficiency per
mRNA remains unchanged. In contrast, changes in translational efficiency can be
observed by shifts along the polysome fractions. For example, if the mRNAs shift
from the light (inefficiently translated) towards the heavy (efficiently translated)
polysome fractions or vice versa in the absence of changes in total mRNA levels
(Fig 1.9 bottom left). Shifts within the heavy polysome fractions (i.e. with a
mean distribution around 4 bound ribosomes to 7 bound ribosomes) can also
occur (Fig 1.9 bottom right). Quantification of mRNA levels within each fraction
can be assessed using Northern blotting or reverse transcription quantitative
polymerase chain reaction (RT-qPCR). For transcriptome-wide studies, efficiently
translated mRNAs are pooled and quantified using either DNA-microarrays or
RNA sequencing.
Pooling of mRNAs as well as collection of multiple fractions makes polysome
profiling inconvenient when dealing with low amounts of input RNA or with large
samples sizes. Therefore, an optimised sucrose gradient was developed where
mRNAs bound to >3 ribosomes are collected on a sucrose cushion and thereby
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can be isolated from one single fraction (Liang et al., 2018). This optimised
gradient allows for application of polysome profiling in small tissue samples where
RNA quantity is limiting and reduces labour intensity of the assay.
Polysome-associated mRNA levels are subject to changes in translation efficiency
as well as factors contributing to cytosolic mRNA levels. Cytosolic mRNA levels
impact the pool of mRNAs that can associate with ribosomes. However, changes
in cytosolic can occur due to, e.g. transcription or mRNA stability. Therefore, to
identify true changes in translation efficiency it is important to collect cytoplasmic
mRNA and polysome-associated mRNA from the same sample in parallel to
correct for such mechanisms during downstream analysis.
1.4.2. Ribosome profiling R17 bacteriophage ribosome protected RNA
fragments (RPFs) have been obtained in the 1960s using ribonucleosases to
trim away mRNA sequences not protected by ribosomes (Steitz, 1969). More
recently ribosome profiling has been developed. Ribosome profiling encompasses
sequencing of RPFs on a transcriptome-wide scale (Ingolia et al., 2009; Ingolia,
2016). Similar to polysome profiling, in the ribosome profiling assay ribosomes
are immobilised on mRNAs using translation elongations inhibitors (e.g. CHX).
RPFs are obtained by RNAse treatment that degrades the links of RNA between
ribosomes leaving single ribosomes covering a ~28 nucleotide long RNA fragment.
However, as ribosomal RNAs (rRNA) are also degraded during this process
they represent a major contaminant herein. The RPFs are then isolated using
ultra centrifugation through a sucrose cushion. During this step other RNA
fragments such as rRNAs, non-coding RNAs (ncRNAs) or large ribonucleoprotein
complexes can co-migrate and contaminate the sample. Typically, RPFs with
a size ranging from 25-30 nucleotides are selected for quantification. However,
RBP-or 43S-protected RNAs, such as those localised in stress granules, may
produce fragments of similar length. Furthermore, ribosomes undergoing
conformational changes have been shown to protect fragments corresponding to
a length of 21nt when translation elongation is blocked by e.g., CHX (Lareau
et al., 2014). Therefore, size selection can distort the estimation of translation
efficiency from ribosome profiling data (Dmitry E. Andreev et al., 2017). From
the resulting RPFs libraries are generated and quantified using RNA sequencing.
During library construction additional biases due to enzyme sequence preferences
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can be introduced that can lead erroneous estimations of codon positions within
the ribosome (Artieri et al., 2014a).
Recently, the algorithm Ribo-seq Unit Step Transformation (RUST) has been
developed (O’Connor et al., 2016). RUST can reveal mRNA sequence features
affecting RPF density globally. The authors applied RUST to 30 publicly available
data sets and identified substantial sequence heterogeneity affecting RPF densities.
Thus, sequence bias is prominent in ribosome profiling (O’Connor et al., 2016).
Initially, fragmented total mRNA using alkaline hydrolysis of the same size were
retrieved in parallel to RPFs. This was achieved by extraction of total mRNA
from cell lysate followed by purification via recovery of polyadenylated messages
or removal of ribosomal RNA (Brar et al., 2015; Ingolia et al., 2009). The random
fragmentation of total mRNA has been shown to result in experimental bias.
Therefore, now sequencing of unfragmented total mRNA in parallel is preferred.
1.4.3. Comparing ribosome and polysome profiling Albeit both methods
generate count data after quantification with RNA sequencing, there are some
key aspects that differ between the techniques. Polysome profiling separates
efficiently translated mRNAs from non- efficiently translated mRNAs along a
sucrose gradient thereby creating an mRNA-based perspective for analysing
changes in translational efficiencies. In contrast, ribosome profiling determines
translational efficiencies by counting the number of RPFs of both efficiently and
non-efficiently translated mRNAs (see figure 1.8). This can have implications for
identification of transcript variants. For example, if a ribosome would not protect
a fragment differentiating two isoforms, information on the isoforms would be lost
during ribosome profiling (Floor et al., 2016). In polysome profiling the integrity
of the mRNA is preserved. This gives polysome profiling the advantage in cases
where transcript variants with different 5’ UTR lengths are of interest. This
makes polysome profiling, but not ribosome profiling, compatible with methods
to investigate UTRs (e.g. CAGE and 3P-seq) (Jan et al., 2011; Takahashi et al.,
2012).
Shifts in ribosome association can be dramatic (e.g. near complete dissociation
of ribosomes from an mRNA) or subtle (e.g. shifts from 2 to 4 ribosomes).
These shifts can occur due to different properties of the mRNAs the ribosomes
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associate with (Gandin, Masvidal, Hulea, et al., 2016). When dramatic and
subtle changes in ribosome association are present in parallel, ribosome profiling
is biased towards identification of shifts with a greater magnitude and masks the
subtle ones (Gandin, Masvidal, Hulea, et al., 2016). Gandin et. al. showed under
mTOR inhibition ribosome profiling studies are likely to predominantly identify
TOP mRNAs (i.e. heavy shifters). In contrast, polysome profiling identified both
TOP and non-TOP mRNAs (i.e. more subtle shifters compared to TOP mRNAs)
when mTOR is inhibited (Gandin, Masvidal, Hulea, et al., 2016). Therefore, in
scenarios where global mRNA translation is affected, application of ribosome
profiling could lead to imprecise biological conclusions. The masking of subtle
changes has been attributed to the indirect estimation of translation efficiencies
from counting RPFs for ribosome profiling, which is highly dependent on the
abundance of mRNAs. In polysome profiling this effect is much less pronounced
as changes in translation efficiency are directly estimated from the mRNAs
associated with heavy polysomes (Masvidal et al., 2017). Therefore, polysome
profiling is more suitable than ribosome profiling in studies that aim to analyse
global changes in translation efficiences. (Gandin, Masvidal, Hulea, et al., 2016;
Masvidal et al., 2017).
An advantage of ribosome profiling is that it provides exact nucleotide positions
occupied by ribosomes. This offers information at a single nucleotide level
where the ribosome is located at the mRNA. Polysome profiling cannot reveal
ribosome locations along the mRNA. The single nucleotide resolution of ribosome
profiling is necessary in contexts studying events such as ribosomal frame shifts
or uORF translation (Dmitry E. Andreev et al., 2015; Rato et al., 2011). One
limitation of ribosome profiling to identify features such as uORFs, is the use
of elongation inhibitors (e.g. CHX) as pre-treatment in the protocol. After
CHX treatment elongation is not immediately inhibited but continues for several
cycles (Hussmann et al., 2015). Studies investigating stress in yeast showed
that increases in ribosome occupancy were due to CHX treatment rather than
stress (Gerashchenko et al., 2014). Therefore, CHX pre-treatment can introduce
biases in ribosome profiling obscuring identification of sequence features that
are potentially important for translational regulation (Gerashchenko et al., 2014;
Hussmann et al., 2015).
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Both methods have their strengths and weaknesses. Thus, when designing an
experiment each method should be considered and chosen depending on the
underlying biological question.







Figure 1.10: Modes for regulation of gene expression - Schematic
representation of modes by which mRNA translation regulates gene
expression. Indicated are: changes of the translation mode, i.e. an
mRNA increases its ribosome association without a change in total
mRNA levels; The mRNA abundance mode, i.e. changes in total
mRNA levels paralleled by changes in translated mRNA levels; The
translational buffering mode, i.e. changes in total mRNA levels
without changes in translated mRNA levels. Also indicated is the
expected outcome on the proteome for all three modes.
From transcriptome-wide
assessments of translation
using ribosome or polysome
profiling expression levels
for both cytoplasmic and
polysome-associated mRNAs
(or RPFs) are obtained. For
simplicity, from now on,
these RNA types will be




mRNA or RPFs). The
estimation of expression levels
for both translated mRNA
and total mRNA allows
distinction between changes occurring at total mRNA level or translation and
their integration. This is important because, the interplay of total mRNA with
translated mRNA can give valuable insights about the underlying mechanisms
that govern gene expression in the studied system.
When comparing perturbed systems to their corresponding control state three
“modes” in which translated mRNA and total mRNA distinctly interact can be
observed (see figure 1.10). These modes are referred to as “mRNA abundance,”
“translation” (i.e. changes in translation efficiencies leading to altered protein
levels) and, “translational buffering” (i.e. changes in translation efficiencies
ensuring stable protein levels across conditions).
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1.5.1. mRNA Abundance mode A change in mRNA abundance is observed
when total mRNA levels change, by e.g. transcription or mRNA stability, but the
translation efficiency of those mRNA is unaltered. (see figure 1.10). The change in
total mRNA levels alters the number of mRNAs to compete for components of the
translation machinery. Thus, their association to ribosomes can be explained by
their abundance. While the translation efficiency for these mRNAs is unaltered, a
modulation of protein synthesis is expected as more or less mRNAs are translated.
1.5.2. Translation mode A change in translation occurs when translated
mRNA levels either increase or decrease, while corresponding total mRNA levels
remain constant or change to a lesser extent (see figure 1.10). The change in
ribosome association independent of total mRNA levels is therefore a change in
their translation efficiency. A prominent example of this mode can be observed
for TOP mRNAs. Under conditions when mTOR is inhibited, TOP mRNAs show
a near complete disassociation from ribosomes (Gandin, Masvidal, Hulea, et al.,
2016). Furthermore, during the ISR, translation of ATF4 mRNA is altered due to
eIF2𝛼 phosphorylation. Similar to changes in mRNA abundance, mRNAs under
the translation mode lead to changes in corresponding protein levels (see figure
1.10).
1.5.3. Translational buffering mode The third mode of regulation of
gene expression is termed translational buffering. Under this mode, a change
in total mRNA levels is observed, whereas polysome-associated mRNA levels
remain constant between conditions. Translational buffering thus reflects a
change in translation efficiency as the proportion of mRNAs associated with
ribosomes is altered. In contrast to changes in translation and mRNA abundance,
translational buffering has been shown to maintain similar protein levels across
conditions rather than inducing alterations to them (See figure 1.10) (Lorent et
al., 2019; McManus et al., 2014).
Current literature supports multiple forms of translational buffering. Translational
buffering can compensate for differences in mRNA levels due to e.g. differences in
gene dosages, so that protein levels remain similar (Dassi et al., 2015; Lalanne et
al., 2018). Furthermore, rather than compensating it can “offset” modulations of
total mRNA levels at the level of translation to maintain corresponding protein
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levels (Lorent et al., 2019).
Translational buffering in its compensation form has been observed at steady
state levels. A study comparing co-evolution of transcription and translation
across seven different organs and mammals showed overall greater divergence
of transcription as compared to translation (Z.-Y. Wang et al., 2020). Similar
compensation at the level of translation has been observed between individuals,
tissues and prokaryotes (Artieri et al., 2014b; Cenik et al., 2015; Dassi et al., 2015;
Lalanne et al., 2018; Perl et al., 2017).
Compensation via translational buffering can also enforce equilibration of pathway
or protein complex stoichiometry (Lalanne et al., 2018; G.-W. Li et al., 2014). An
example of this was observed in evolutionary distant bacteria, i.e. B. subtilis and
E. coli. In B. subtilis translation related factors rpsP and rplS are located in
different operons, whereas in E. coli rpsP and rplS lie within the same operon
as rimM and trmD. While B. subtilis can fine tune transcription at the different
operons, in E. coli these will be transcribed together. However, in E. coli rimM
and trmD are only required in low protein abundance, whereas rpsP and rplS are
required in high abundance. E. coli compensates the transcriptional input at the
translational level and thus equilibrates for requirements in pathway stoichiometry
(Lalanne et al., 2018).
As mentioned above, a different form of translational buffering can be observed
in perturbed systems that offset changes in total mRNA levels at the level of
translation temporarily. For example, translational offsetting was observed in
prostate cancer cells where a transcriptional program was induced under estrogen
receptor 𝛼 (ER𝛼) depletion that showed no increase in polysome-associated
mRNA. mRNAs whose transcription was translationally offset required the tRNA
U34 modification. ER𝛼 has been shown to regulate the expression of the catalytic
enzymes required for the U34 modification (Lorent et al., 2019). Thus, depletion
of ER𝛼 led to impeded modification of tRNAs at the U34 position. Therefore,
the translation efficiency of mRNAs requiring the modification was reduced
despite increased total mRNA levels. The authors confirmed that protein levels
of translationally offset mRNAs were unaltered between conditions (Lorent et al.,
2019).
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1.6. Algorithms for analysis of changes in translation efficiencies
As discussed above, the proteome can be reshaped via multiple modes for
regulation of gene expression. Furthermore, these modes can have different
underlying mechanisms. It is therefore warranted to distinguish them in
analysis of translation efficiencies. This section discusses methods to analyse
polysome-profiling and ribosome profiling data to estimate changes in translation
efficiencies across 2 or more conditions.
Initially, analysis of transcriptome-wide translation studies used an approach







This score calculates the ratio of the ratios between polysome-associated mRNA
levels (P) divided by total mRNA levels (T) within each condition, i.e. C1 and
C2. The TE- score approach has been shown to be prone to spurious correlations
(Larsson et al., 2010). Spurious correlations arise due to that the ratio of
polysome-associated mRNA and total mRNA can systematically correlate with
total mRNA levels which is not corrected for in this equation and leads to an
elevated type-1 error.
Figure 1.11 gives an overview of the relationship between a change in TE-score
and each gene expression mode (see also figure 1.10). Changes in mRNA
abundance will lead to a ∆TE close to 0 in log space (i.e. no change in translation
efficiency). This is due to that total mRNA and translated mRNA change with
a similar magnitude. However, in the case of both the translation mode and the
translational buffering mode, the nominator and denominator in the TE-score
equation change leading to a ∆TE (TE < 0 or TE > 0). Therefore, the TE-score
cannot distinguish between changes belonging to the translation mode from
changes of the translational buffering mode. This can have drastic consequences































Figure 1.11: TE-scores for modes for regulation of
gene expression - Schematic representation of modes
for regulation of gene expression in a fold-change
scatter plot. The x-axis indicates the fold-change
for total mRNA levels. The y-axis indicates the
fold-change for translated mRNA levels. Indicated in
red are changes in translation efficiency altering protein
levels (i.e. translation mode), in green changes in
mRNA abundance and in blue changes in translation
efficiency leading to translational buffering/offsetting.
The relationship for the TE-score and the modes for
regulation of gene expression is indicated.
The TE-score approach was questioned
when proposing the Analysis
of Translation Activity (anota)
algorithm which was developed for
DNA-microarray data (Larsson et
al., 2010). Anota combines analysis
of partial variance (APV) (Schleifer
et al., 1993) with a random variance
model (RVM) (Wright et al., 2003).
RVM estimates gene variance using
shared information across all genes
to increase power for detection of
differential expression (Wright et
al., 2003). Anota uses a two-step
process that firstly assesses the model
assumptions for (i) absence of highly
influential data points, (ii) samples
classes sharing a common slope, (iii)
homoscedasticity of residuals and
(iv) normal distribution of per gene
residuals. In the second step anota performs analysis of changes in translational
activity using the following model:
𝑦𝑔𝑖 = 𝛽𝑅𝑁𝐴𝑔 𝑋𝑅𝑁𝐴𝑖 + 𝛽𝑐𝑜𝑛𝑑𝑔 𝑋𝑐𝑜𝑛𝑑𝑖 + 𝜀𝑔𝑖
here 𝑦𝑔𝑖 is the polysome associated mRNA expression, 𝛽𝑅𝑁𝐴𝑔 describes the
relationship to total RNA for the 𝑔𝑡ℎ gene of the 𝑖𝑡ℎ sample column of model
matrix 𝑋; 𝛽𝑐𝑜𝑛𝑑𝑔 represent the difference in intercept between treatment classes



































































Figure 1.12: anota gene models - Schematic
representation of the anota analysis models. Translated
mRNA expression is set out against total mRNA
expression for each biological replicate and treatment
condition. Top left shows the model of a gene that
is differentially translated (i.e. change in translated
but not total mRNA). The difference in the slope
intercepts is used to estimate changes in translation
efficiencies between conditions. Other gene models
are shown; change in translation efficiency leading to
altered protein levels with varying total mRNA levels
(top right); change in mRNA abundance (bottom left)
and translational buffering (bottom right).
Within anota, a common slope for the
treatment classes that describes the
relationship between translated mRNA
and total mRNA is calculated. The
difference between the slope intercepts
is then interpreted as the change in
translation efficiency. A simplified
view of this model is provided in
(Figure 1.12 top left). Here, expression
for translated mRNA and total mRNA
are modeled over two sample classes
that each has 4 replicates. Changes
in translation efficiencies can also
be observed when translated mRNA
expression is modulated to a larger
extent than the total mRNA levels
(Figure 1.12 top right). Identification
of genes in this category can be a
challenge, especially in highly variable
data sets, as they resemble genes
regulated at the level of mRNA abundance (Figure 1.12 bottom left). Nevertheless,
using the linear regression analysis anota accurately corrects changes in translated
mRNA as can be seen in (Figure 1.12 bottom right). Here, a change in total
mRNA but not translated mRNA levels is observed. For this gene, the difference
in slope intercepts between sample classes is small and will not be identified as
differentially translated as would be the case in the TE-score approach. Anota
was developed at a time where translational buffering was not considered in data
sets. Naturally, the method lacks a setting to analyse translational buffering. This
was addressed in anota’s successor, anota2seq, and will be discussed in Study 1.
Advances in experimental methods warrant for appropriate statistical approaches
to analyse data resulting from them. DNA-microarray was the dominant
platform to assess transcriptome-wide changes before the advent of RNA
sequencing. DNA-microarrays measure intensity after hybridisation events
which is an indicator of expression. In contrast, in RNA sequencing reads of
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constructed libraries are counted. Intensity data from DNA-microarray can be
normalised and transformed (i.e. log transformation) to fulfill the requirements
for application of linear models, whereas RNA sequencing harbours additional
characteristics that need to be accounted for. Therefore, algorithms developed
for analysis of DNA- microarray are not directly applicable to RNA sequencing
data as is the case for the anota algorithm.
RNA sequencing data shows variance that is greater than the mean which is
commonly referred to as overdispersion. Count data from RNA sequencing
have been initially approached using Poisson distributions which assumes
that the variance is equal to the mean (Lu et al., 2005). Now established
RNA sequencing analysis frameworks such as edgeR and DESeq2 use negative
binomial distributions in combination with generalised linear models (GLMs)
(Love et al., 2014; Robinson et al., 2010). The negative binomial distribution
uses a dispersion parameter to account for differences in the mean-variance
relationship across the expression range (McCarthy et al., 2012). While analysis
principles of DESeq2 and edgeR are similar, they differ in their normalisation
method, dispersion estimation and information sharing across genes. In a simple
differential expression analysis between two conditions with one RNA type the
GLM model would be as in the following equation:
𝑙𝑜𝑔(𝑦𝑔𝑖) = 𝛽𝑐𝑜𝑛𝑑𝑔 𝑋𝑐𝑜𝑛𝑑𝑖 + 𝜀𝑔𝑖
here 𝛽𝑐𝑜𝑛𝑑𝑔 𝑋𝑐𝑜𝑛𝑑𝑖 represent the condition (i.e. control and treatment) log2 fold
change for the 𝑔𝑡ℎ gene 𝑖𝑡ℎ sample column of the model matrix X and 𝜀𝑔𝑖
denotes the residual error. When analysing changes in translation effiencies
additional parameters for RNA type (i.e. total mRNA or translated mRNA) and
the interaction between the RNA type and condition are added so that:
𝑙𝑜𝑔(𝑦𝑔𝑖) = 𝛽𝑅𝑁𝐴𝑔 𝑋𝑅𝑁𝐴𝑖 + 𝛽𝑐𝑜𝑛𝑑𝑔 𝑋𝑐𝑜𝑛𝑑𝑖 + 𝛽𝑅𝑁𝐴∶𝑐𝑜𝑛𝑑𝑔 𝑋𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑖 + 𝜀𝑔𝑖
In this model, the interaction term is interpreted as the change in translation
effiencies (Chothani et al., 2019). Other methods (i.e. Ribodiff (Zhong et al.,
2017), Riborex (W. Li et al., 2017) and deltaTE (Chothani et al., 2019)) borrow
32
this analysis principle of an GLM with an interaction term by applying this
exact model. A notable difference is that Ribodiff allows dispersion estimation
for translated mRNA and total mRNA separately. Differences in within-RNA
variances between RNA types can be expected due to varying experimental
protocols (Liang et al., 2018; Zhong et al., 2017). While the flexibility of GLMs
allows for complex study designs involving 2 or more treatment conditions,
Riborex and Ribodiff limit the study design to only two conditions. DeltaTE
gives their users full flexibility of the DESeq2 GLM model. Xtail is a method
developed for ribosome profiling that makes use of DESeq2 for RNAseq count
normalisation (Z. Xiao et al., 2016). Their assessment of differences in translation
efficiencies relies on probability matrices for the ratio of translated mRNA over
total mRNA within condition and a between condition ratio of these ratios. Babel
was the first algorithm designed solely for analysis of differential translation
and uses an error-in-variables regression analysis (Olshen et al., 2013). The
error-in-variables regression allows accounting for variable total mRNA levels
when assessing changes in translation. Although these methods have distinct
approaches to identify changes in translation efficiencies, their principle of
analysis is similar to comparing a ratio of ratios (see TE-score equation above).
Therefore, these methods suffer from similar issues as the TE-score which will be
discussed in Study 1.
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2. Aims of this thesis
This thesis aims to expand current methodologies for analysis of translation
efficiency data and explore the regulation of gene expression in cancer.
In Study I, we adapted the ANalysis Of Translation Activity data (anota)
algorithm so that it could be applied to next-generation sequencing data.
Furthermore, we implemented the analysis of translational buffering a recently
described mode for regulation of gene expression. The resulting algorithm was
named anota2seq.
We then applied the anota2seq algorithm to investigate changes in translation
efficiencies in two cancer models:
In Study II we unravelled the effects of eIF4A, an RNA helicase, inhibition using
a synthetic rocaglate CR-1-31-B (CR-31) in pancreatic ductal adenocarcinoma.
In Study III we explored the effects of insulin on gene expression in multiple cell
lines.
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3. Results and discussion
3.1. Study 1 - Generally applicable transcriptome-wide analysis of
translation using anota2seq
Initially, changes in translation efficiencies were estimated using the TE-score
approach as outlined in section 1.6. However, this method was shown to be prone
to spurious correlations. This leads to elevated false positive identification that
can result in erroneous biological conclusions (Larsson et al., 2010). When using
the TE-score, spurious correlations can be attributed to the inadequate correction
for changes in total mRNA levels when estimating translation efficiencies (Larsson
et al., 2010, 2011). The Analysis of Translation Activity (anota) algorithm
facilitates analysis of translational efficiencies that are corrected for changes in
total mRNA levels (Larsson et al., 2011).
Anota was developed for analysis of transcriptome-wide analysis for data
quantified by DNA- microarrays (Larsson et al., 2010). However, advances in
experimental methodologies lead to the development of RNA sequencing. RNA
sequencing and DNA microarray data have distinct characteristics that need
to be accounted for before analysis (see section 1.6). Therefore, while the
statistical framework of anota was shown as an adequate approach for analysis of
translational efficiencies DNA microarray data, it was not directly applicable to
RNA sequencing data (see section 1.6). Efforts have been made to make RNA
sequencing data more “DNA-microarray-like” so that algorithms developed for
intensity based microarray data can be applied to count based RNA sequencing
data (Law et al., 2014; Love et al., 2014). Anota2seq, the algorithm developed in
this study, allows for transformation and normalisation of RNA sequencing data
so that the anota statistical framework can be applied for analysis of count data.
Another feature of anota2seq is that it allows for statistical analysis of
translational buffering. The need for the analysis of translational buffering, or
the uncoupling of total mRNA levels from translation, has been noted before
anota2seq’s development by comparing 20 translatomes and transcriptomes with
different underlying stimuli in mammalian cells (Tebaldi et al., 2012). The
same authors proposed a framework, called tRanslatome, that combines several
methodologies for analysis of differential transcription and translation efficiencies,
including anota, for a comprehensive analysis of transcription and translation as


















Figure 3.1: anota2seq gene model for analysis
of translational buffering /offsetting - Total mRNA
expression is set out against translated mRNA
expression for each biological replicate and treatment
condition. The model shows total mRNA changes
that are independent of translated mRNA changes, i.e.
translational buffering (see section 1.5).
Nevertheless, commonly observed in
polysome and ribosome profiling data
sets are three gene expression modes,
translation, translational buffering
and mRNA abundance. While anota
can be used to identify genes among
the translation and mRNA abundance
modes, analysis of translational
buffering was not implemented therein
(See Figure 1.12). Therefore, one
would need to rely on the integration
of several methods to efficiently
analyse transcriptome-wide studies
of translation efficiencies. Anota2seq
addresses this issue by changing
the analysis model as described in
section 1.6 to analyse changes in total
mRNA levels corrected for changes in
translated mRNA levels (i.e. translational buffering, see figure 3.1).
Application of anota2seq has successfully identified translational buffering to
which biological mechanisms could be linked (Lorent et al., 2019). Furthermore,
in study 2 translational buffering can be observed as a compensating mechanism
in “healthy” cells upon treatment with an eIF4A inhibitor and in study 3 we
identify mTOR dependent translational buffering for mRNAs with certain 3’
UTR characteristics.
The aim of this study was to compare anota2seq’s performance to other established
algorithms (i.e. DESeq2, RiboDiff, babel, TE-score and Xtail) for analysis of
translation efficiencies. More specifically, we were interested in their ability
to distinguish the three prominent modes of gene expression (see figure 1.10).
To achieve this we used simulated data. While it is arguable to what extent
conclusion drawn from simulated data can be extended towards empirical data,
it allows for a controlled environment where true positive changes are known in
advance. The mean-variance relationship in the simulated data is based on a real
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polysome profiling data set to increase confidence that drawn conclusions are also
applicable to empirical data (Guan et al., 2017). Furthermore, during testing of
our simulation we used an additional data set to estimate parameters from to
generate data sets. Using these simulated data to compare the performance of
the above mentioned algorithms showed almost identical results.
The simulated data consisted of four replicates for translated mRNA and total
mRNA with a “control” and a “treatment” condition. The data sets also contained
a combination of the following gene sets:
Unchanged: For this simulation category we sampled reads from the same NB
distribution for both the control and treatment conditions in both the translated
and total mRNA. This category represents genes that would be unaffected by
e.g. a stimulus.
mRNA abundance: For this category the control condition for both the translated
mRNA and total mRNA were sampled from the same NB distribution. The NB
distribution for both translated mRNA and total mRNA of the treatment
condition was altered so that values would be drawn corresponding to a fold
change (negative or positive) ranging between 1.5 to 3.0. The directionality of the
fold changes (i.e. up or down regulation) was the same for translated mRNA and
total mRNA.
translation: For this category the control condition for both the translated
mRNA and total mRNA were sampled from the same NB distribution. The
NB distribution for translated mRNA only of the treatment condition was
altered so that values would be drawn corresponding to a fold change (negative
or positive) ranging between 1.5 to 3.0.
buffering: For this category the control condition for both the translated mRNA
and total mRNA were sampled from the same NB distribution. The NB
distribution for total mRNA only of the treatment condition was altered so
that values would be drawn corresponding to a fold change (negative or positive)
ranging between 1.5 to 3.0.
As a first step, we tested whether the methods could properly control for type-1
errors (i.e. false positive identification). For this we simulated a data set with
genes belonging only to the “unchanged” category. This revealed that babel,
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but to an even greater extent Xtail, were unable to control their type-1 error
as these methods assigned low p-values and FDRs when no real changes were
present. DESeq2 was marginally affected by this also. This indicated a limited
applicability of Xtail and babel for statistical analysis of translatomes.
From the comparative analysis of the analysis for changes in translation
efficiencies affecting protein levels we concluded that anota2seq outperforms all
other methods. This was assessed by comparing the area under the curve from
Receiver operating characteristics (ROC) and precision recall curves. The ROC
curves showed a, albeit slightly, better performance for detecting changes in
translation. However, the precision recall was much higher for anota2seq. This
can be accredited to that the analysis principle of the other methods is similar
to the TE-score (as explained in section 1.6). Nevertheless, when comparing
the performance using simulated data in the absence of genes belonging to the
“buffering” category anota2seq still showed superior performance.
Knowing the simulated true changes in advance allowed us to modify parameters
to investigate the robustness of the methods to increased variance, overall
sequencing depth and differing sequencing depth between samples. Here, all
methods showed robustness against variance, sequencing depth, and differences
in sequencing depth between samples as long as a minimum of 5 million counts
per sample was reached.
A shortcoming in the simulation study is that we did not assess the effects of
systematic batch effects for all methods. Batch effects can be introduced during
experimental design and can reduce statistical power. Currently there are many
methods that try to correct for batch effects when present in the data (Johnson
et al., 2007; Leek, 2014; Y. Zhang et al., 2020). Other ways to correct for batch
effects is to include them in the analysis model. For instance, Anota2seq, edgeR
and DESeq2 allow for incorporation of batch effects in their analysis models.
Indeed, analysis of a dataset with prominent batch effects showed that batch
effects can dampen the efficiency of the anota2seq algorithm to identify changes.
However, including a batch correction in the analysis model of anota2seq increased
statistical power to detect changes drastically.
In this study, we developed an analysis algorithm for efficient transcriptome-wide
analysis of translation efficiencies applicable to DNA-microarrays and RNA
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sequencing. Furthermore, anota2seq has been successfully applied to broaden
the knowledge around mRNA translation in various different contexts (Chan
et al., 2019; Chaparro et al., 2020; Hipolito et al., 2019; Lorent et al., 2019).
Furthermore, more recently anota2seq has been used to compare mRNA levels
between cytoplasmic mRNA and mRNA stored in P-bodes showcasing that
anota2seq is generally applicable beyond analysis of translation efficiencies
(Bearss et al., 2021).
3.2. Study 2 - eIF4A supports an oncogenic translation program in
pancreatic ductal adenocarcinoma
Pancreatic cancer is considered a lethal malignancy and has limited treatment
options. While other cancers (e.g. ovary, breast and stomach) showed a decline
in mortality rates, no major overall reduction in mortality was observed for
pancreatic cancer in the period of 1970-2020 (Carioli et al., 2021).
Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of exocrine
pancreatic cancer, whereas non ductal pancreatic cancers e.g. acinar cell
carcinomas are uncommon (Feldmann et al., 2007; Jun et al., 2016). It is
estimated the 60-70% of the PDACs arise in the head of the pancreas (Luchini
et al., 2016). So far treatment options are mostly limited to surgical removal,
which often is impossible due to the anatomical location of the pancreas head.
The 5-year survival rate for this disease is less than 10% (Rawla et al., 2019).
A Dutch nationwide study indicated that in cases where surgical removal was
possible 5-year survival only increased from 9.1% to 16.5% (Latenstein et al.,
2020).
With the increasing understanding of tumour heterogeneity, anti-cancer therapy
improved (Biankin et al., 2011). For example, in breast cancer stratification
by histological, molecular and gene expression features identified several breast
cancer subtypes for which different treatment options exist, e.g. 𝐸𝑅+ breast cancer
subtypes respond to endocrine therapy, whereas 𝐸𝑅− do not (Andre et al., 2006;
Parker et al., 2009). While breast cancer treatment strategies benefit from a rather
well established understanding of the molecular subtypes, in pancreatic cancer
transcriptomic based subtyping is still ongoing (Bailey et al., 2016; Collisson et
al., 2011; Collisson et al., 2019; Moffitt et al., 2015; Puleo et al., 2018). Therefore,
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insufficient understanding of molecular mechanisms that underpin PDAC hinder
development of more efficient therapeutic approaches.
While intricacies of molecular subtypes are still being investigated, research has
shown that oncogenic mutations in KRAS as well as inactivation of tumour
suppressor TP53 are commonly shared among PDACs (Jones et al., 2008).
Furthermore, PDACs have been shown to be dependent on increased protein
synthesis induced via KRAS mutations (Chio et al., 2016). This indicates an
important role of mRNA translation in PDAC.
The aim of study 2 was to investigate the therapeutic effects of targeting eIF4A
in a murine three dimensional PDAC organoid cell culture with mutations
in the 𝐾𝑟𝑎𝑠𝐿𝑆𝐿−𝐺12𝐷, 𝑇 𝑟𝑝53𝐿𝑆𝐿−𝑅172𝐻 and Pdx1-cre alleles that has been
shown to recapitulate PDAC tumour progression (Boj et al., 2015). Pancreatic
and duodenal homeobox 1 (PDX1), is an important factor for pancreatic
differentiation. PDX1 knock out mice failed to develop a pancreas (Hale et
al., 2005). The inhibition of eIF4A was carried out using a synthetic rocaglate,
CR-31. Rocaglates have been shown to inhibit eIF4A helicase function and
display anti-tumour activity (Cencic et al., 2009).
We first wanted to establish the therapeutic validity of targeting eIF4A in PDAC.
In vitro experiments comparing treated PDAC organoids (KP) to their normal (N)
counter parts revealed heightened sensitivity of KP organoids to CR-31 treatment
relative to N organoids. OP-puromycin incorporation showed reduced protein
synthesis in KP organoids, whereas N organoids were affected to a lesser extent.
Furthermore, similar effects were found in vivo for PDAC tumours. Here, CR-31
reduced protein synthesis (assessed by SUnSET assay), tumour growth (assessed
by ultra sound imaging) and increased survival of mice. The effect on protein
synthesis was not due to inhibition of oncogenic signalling pathways which was
evaluated via western blot assessing the phosphorylation of e.g. AKT, mTOR and
4E-BP1. From these findings we concluded that there is therapeutic validity in
targeting eIF4A in PDAC.
Using polysome profiling, we then sought to decipher the mechanisms explaining
the increased sensitivity to CR-31 in KP organoids. First, we investigated the
differences in gene expression between untreated KP organoids and N organoids.
Analysis of changes in translation efficiencies using anota2seq revealed massive
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modulation at both total mRNA and translated mRNA levels in KP organoids
relative to N organoids. This is indicative of the underlying differences in
e.g. genomic stability and enhanced oncogenic signalling impinging on protein
synthesis reported in PDAC (Boj et al., 2015).
We then compared the translatome of treated KP organoids to the differences
between untreated KP organoids and N organoids. Treatment of KP organoids
with CR-31 reversed the changes of untreated KP organoids as compared to
N organoids. Furthermore, CR-31 treatment in N organoids had no apparent
effect on mRNA translation. This is consistent with the in vitro OP-puromycin
incorporation and in vivo SUNsET experiments, CR-31 strongly impacted global
protein synthesis in KP organoids, while only exerting a modest effect in N
organoids. Nevertheless, mRNAs affected by CR-31 in KP organoids showed
modulated total mRNA levels in N organoids that were offset at the level of
translation. Translational offsetting has been shown to keep protein levels
constant despite alterations in total mRNA levels (Lorent et al., 2019). The
ability for N organoids to modulate total mRNA levels for mRNAs of which
translation is affected in KP organoids by CR-31 could partially explain as to
why protein synthesis is not reduced to a similar extent in N organoids as in KP
organoids.
We then assessed 5’ UTR characteristics of the mRNAs whose translation
was affected upon CR-31 treatment in KP organoids. It was reported that
eIF4A-senstive mRNAs showed overall longer and more structured 5’ UTRs
(e.g. containing G-quadruplexes) (Gandin, Masvidal, Hulea, et al., 2016; Rubio
et al., 2014; Wolfe et al., 2014). Furthermore, a mechanisms by which rocaglates
would clamp eIF4A to mRNAs with [A,G] repeats in their 5 UTR was described
(Iwasaki et al., 2016). However, mRNAs sensitive to CR-31 treatment herein
had short 5’ UTRs that were more structured when corrected for their length
without enrichment for G-quadruplexes or [A,G] repeats. Therefore, CR-31
sensitive mRNAs in KP organoids show 5’ UTR characteristics different from
those reported in the literature (see section 1.3.1.2.2). However, based on our
polysome profiling and 5’ UTR analysis, we concluded that eIF4A supports an
oncogenic translation program in PDAC cells for mRNAs with shorter but more
structured 5’ UTRs as compared to our background set (i.e. all non-regulated
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mRNAs).
Translation of mRNAs harbouring short 5’ UTRs and long 5’ UTRs has been
shown to be sensitive to eIF4E expression (Gandin, Masvidal, Hulea, et al., 2016).
When we compared an eIF4E overexpression signature in the KP vs N and CR-31
treated KP we observed that in KP organoids translationally regulated mRNAs
under eIF4E overexpression were also translationally activated. This observation
is consistent with reports of 4E-BP1 loss in pancreatic cancer and consequently
increased ability of eIF4E to engage in the eIF4F complex (Martineau et al., 2014).
eIF4A inhibition in tumours resistant to mTOR inhibition by loss of 4E-BP1 has
been shown to circumvent this resistance (Müller et al., 2019). CR-31 treatment
in KP organoids reversed the translational profile for eIF4E-sensitive mRNAs.
We further inspected the regulated gene sets in treated and untreated KP
organoids compared to N organoids. Here, we could see an enrichment
in metabolic pathways, e.g. oxidative phosphorylation. Th oxidative
phosphorylation pathway was upregulated at the polysome associated mRNA
level in untreated KP organoids compared to N organoids, whereas in KP
organoids CR-31 treatment reversed the translational profile of this pathway.
Furthermore, CR-31 treatment in KP organoids lead to reduced oxygen
consumption rates, whereas N organoids where affected to a lesser extent. While
measuring oxygen consumption rates do not rule out that non-mitochondrial
sources are affected, we attributed the observed decrease in oxygen consumption
to defective oxidative phosphorylation.
A way to counter loss of energy production through oxidative phosphorylation
is to increase activity of other metabolic pathways, i.e. glycolysis. However, in
CR-31 treated KP organoids we could not detect an upregulation of glycolysis
measured by 𝑈 −𝐶13 glucose labelling and extra cellular acidification rates nor did
CR-31 treatment affect expression of glycolytic enzymes (e.g. HK1,HK2, LDHA,
SLCA1, SLCA3). Furthermore, glucose deprivation did not further sensitise to
CR-31 treatment. However, the polysome profiling data revealed translational
downregulation and subsequent reduction of protein expression for the glucose
transporter Slc2a6. Indeed, perturbation of Slc2a6 using 𝑠𝑔𝑅𝑁𝐴𝑆𝑙𝑐2𝑎6 in N and
KP organoids revealed a decrease in glucose uptake. From this we concluded that
glycolytic compensation of KP is diminished by translational regulation of the
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glucose transporter Slc2a6 upon CR-31 treatment.
Among the translationally activated genes in the CR-31 treated KP organoids
where mRNAs involved in the glutamine metabolism (i.e. Slc1a5 and Gls1).
Furthermore, glutamine levels were elevated in patient derived PDAC cell lines
treated with CR-31. Glutamine can be converted into 𝛼-ketoglutarate which
can undergo reductive carboxylation to produce citrate (D. Xiao et al., 2016).
Indeed, using gas chromatography mass spectrometry (GC/MS) to quantify
metabolites after labelling PDAC cells in 𝐶135 -glutamine, we identified a shift
towards reductive carboxylation of 𝛼-ketoglutarate obtained from 𝐶135 -glutamine
to produce citrate. Notably, the reductive glutamine metabolism was not elevated
in N organoids.
A combined treatment of CR-31 with glutaminase inhibitors (BPTES or CB839)
could sensitise to CR-31 treatment patient-derived PDAC cells to CR-31
treatment indicating that glutamine utilisation is important therein. Therefore,
our study suggests an eIF4A dependent translational program in PDAC that can
act as a therapeutic target in PDAC. Furthermore, a recently published observed
the same therapeutic effect of CR-31 treatment in vivo on survival and tumour
volume (Singh et al., 2021). This underlines the significance of our study in
identifying eIF4A as therapeutic target in PDAC.
Nevertheless, the same study indicated differences on 5’ UTR characteristics of
eIF4A-sensitive mRNA subsets (Singh et al., 2021). They report, in line with
the literature, that eIF4A dependent mRNAs show long and structured 5’ UTRs
containing 𝐺𝐺𝐶4 sequence motifs they propose to form G-quadruplexes (Singh
et al., 2021). The 5’ UTR characteristics of the mRNAs proposed in our study
resembled more those of mTOR-eIF4E sensitive mRNAs proposed by Gandin
et al., i.e. shorter 5’ UTRs as compared to our background (Gandin, Masvidal,
Cargnello, et al., 2016). This raises some questions about the differences between
experimental setups and their potential influence on biological outcomes and
interpretation thereof. For instance, Singh et. al. performed ribosome profiling
on a PANC1 cell line culture treated with 25nM CR-31, whereas herein we
performed polysome profiling on a 3D-organoid culture treated with 10nM CR-31.
The differences between ribosome and polysome profiling have been discussed
extensively (see section 1.4). Furthermore, by measuring IC50 concentrations
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for CR-31 in a panel of pancreatic cancer cell lines, Singh et. al. show a ~6-fold
difference in susceptibility to CR-31 between the cell lines of which PANC1 cells
were most sensitive to CR-31. Dosage dependent viability experiments of patient
derived PDAC cells in our study revealed that at 10nM CR-31 treatment cell
viability was reduced by ~30%, whereas treatment with 25nM reduced viability
by > 50%. Furthermore, in patient derived PDAC at 25nm CR-31 a combination
treatment of CR-31 and CB839 did not alter cell viability compared to CR-31
treatment alone. However, at 12.50nM CR-31 treatment, combined treated
with CR-31 and CB839 further reduced viability. Therefore, combining the
findings of these two studies indicate that CR-31 treatment in PDAC indeed has
a therapeutic effect. However the underlying mechanisms that are observed in
the transcriptome-wide analysis of translation efficiencies could be dependent on
the experimental method to assess mRNA translation, the model system and
drug concentrations. Therefore, further research is warranted to resolve these
discrepancies and better understand the regulation of mRNA translation upon
eIF4A inhibition in PDAC.
3.3. Study 3 - Insulin signalling gene expression landscapes distinguish
non-transformed vs. BCa cells
An important factor to consider in breast cancer treatment are life style and
other health related issues that could impact cancer progression or response to
treatment, e.g. obesity. Studies in the 1970 observed unfavourable prognosis for
breast cancer in obese women (Abe et al., 1976). Obesity can pose an increased
risk to develop metabolic disorders such as metabolic syndrome or type 2 diabetes
that can lead to hyperinsulinemia, i.e. elevated physiological insulin levels (Saltiel,
2001).
The role of insulin in the body is to regulate glucose and lipid metabolism as well as
protein synthesis of which dysregulation are hallmarks of cancer (Hanahan et al.,
2011; Saltiel, 2001). Insulin binds to insulin receptor (IR) A and B that activate
the PI3K/AKT/mTOR and mitogen activated protein kinase (MAPK) signalling
pathways. A role of insulin in cancer progression has initially been observed in long
term tissues cultures where it increased metabolism as well as growth (Osborne
et al., 1976). IGFs (i.e. IGF1 and IGF2) carry out similar roles as insulin and
bind to insulin-like growth factors receptor 1 (IGFR1). Insulin and IGFs can
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bind to either IRs or IGF1R. Furthermore, IRs and IGF1R have been shown to
form homo- and heterodimers, e.g. IR-A/IGF1R dimers. Because they act on
same receptors, insulin and IGFs activate the same signalling pathways albeit
with different affinities (Boucher et al., 2010; Pollak, 2008). Additionally, IGF1
plays a role in cancer progression and its levels are elevated upon hyperinsulinemia
(Bailyes et al., 1997; Christopoulos et al., 2015; Gallagher et al., 2010; Molinaro
et al., 2019).
The importance of both IGF1 and insulin signalling in cancer is well-established
and led to development of therapeutic strategies by e.g. targeting both IGF1R and
IR or the PI3K signalling pathway (Kuijjer et al., 2013; Mayer et al., 2017). Yet,
to this day the full mechanism of insulin/IGF action in cancer remains poorly
understood. This study aims to bridge this gap in knowledge by elucidating
the effects of insulin signalling on gene expression using a multi-omics (including
transcriptomics, translatomics and proteomics) approach to capture multiple steps
of the gene expression pathway simultaneously. Furthermore, we assess insulin
signalling in cancer cells as well as non-transformed epithelial cells.
We first investigated the effects of insulin on gene expression in a luminal A
breast cancer cell line, i.e. MCF7 cells. MCF7 cells harbour the E545K PI3KC
mutation and are sensitive to insulin stimulation. Polysome-profiling revealed a
strong modulation of total mRNA levels and translational response upon insulin
stimulation. Among the translationally activated mRNAs were mRNAs with short
5’ UTRs that harboured TOP motifs which is in accordance that insulin signalling
leads to activation of mTORC1 and phosphorylation of its downstream targets.
When visualising the upon stimulated translationally activated mRNAs in MCF7
in the data where MCF7 cells were stimulated with insulin in the presence of
torin1, we observed that the changes in mRNA translation were almost fully
reversed. Torin1 is an mTOR active site inhibitor. This led to the conclusion
that the effects of insulin on gene expression are to a great extent dependent on
mTOR activity.
What was surprising to us was the observation that a subset of mRNAs
exhibited translational buffering upon insulin stimulation while mTOR is
inhibited. For these mRNAs, the total mRNA levels were increased, whereas
the polysome-association was unaltered between conditions Thus, changes in
45
total mRNA levels where offset at the level of translation. Using high resolution
isoelectric focussing (HiRIEF) LC/MS we show that translationally offset mRNAs
maintain constant protein expression across conditions (Branca et al., 2014).
The ability of translational offsetting to maintain constant protein levels across
conditions despite alterations in total RNA levels has been shown by others
before (Lorent et al., 2019). These findings indicate that mTOR can act as a
gatekeeper for modulations of total mRNA levels to fine tune translation in
response to extra cellular or intra cellular signals.
MCF7 cells are of epithelial origin and therefore not “classical” insulin-sensitive
such as adipose tissue or muscle cells. The strong response of MCF7 cells to
insulin prompted us to investigate whether this could be an adapted mechanism
in cancer. To assess this we chose to compare the effects found in MCF7 to a
non-malignant epithelial cell type, i.e. HMEC cells. We found that insulin alone
was not sufficient to stimulate the PI3K/AKT/mTOR pathway in HMEC to a
similar extent as in MCF7. However, a combination treatment of insulin and IGF1
in HMEC cells elicited a similar response as insulin treatment in MCF7 alone. We
therefore opted to compare the combined insulin + IGF1 treatment in HMEC to
that of MCF7 assuming their signalling cascades are nearly identical as proposed
in the literature (Boucher et al., 2010; Pollak, 2008).
Polysome profiling of the insulin + IGF1 stimulated HMEC cells revealed a
strong translational response which was similar to MCF7 cells. Translationally
activated mRNAs in HMEC showed 5’ UTR features similar to those in MCF7
cells. Consequently, their translational activation was dependent on mTOR
signalling evident from their translational suppression under conditions when
mTOR was inhibited during insulin + IGF stimulation. Furthermore, comparing
the mRNA signatures of HMEC in the expression data originating from MCF7,
and vice versa, we suggested that changes at the level of translation were almost
fully in accord across cell types.
In contrast to MCF7 cells, HMEC did not elicit a strong modulation of total
mRNA levels as shown by the small number of changes in mRNA abundance.
When comparing a recently described transcription signature induced after
IR translocation to the nucleus, we could see that in both HMEC and MCF7
these mRNAs show changes in total mRNA levels but of differing magnitude
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(Hancock et al., 2019). A possible explanation for the different response in
total mRNA levels between the cell clines could be due to differences in,
e.g. chromosome instability that expose different parts of the DNA to trans
acting factors. While not assessed herein, a transcription factor analysis paired
with chromatin immunoprecipitation (ChIP) sequencing could provide insight
into this (Park, 2009; Solomon et al., 1988). Assuming a consequence of having a
weaker modulation of total mRNA levels, HMEC cells did not elicit translational
offsetting upon insulin + IGF1 stimulation when mTOR was inhibited. Thus,
the effects of insulin and IGF1 signalling on mRNA translation are foremost
mTOR dependent, however total mRNA responses differ between malignant and
non-malignant epithelial cells.
The translational offsetting in MCF7 drove us to investigate this phenomenon
more. To assess differences dependent on mRNA characteristics we defined two
subsets. The “reversed” and the “uncoupled” (that is translationally buffered
when mTOR is inhibited) subsets that only differed in their total mRNA response
when mTOR was inhibited during insulin stimulation. To rule out that the
observed effects on total mRNA are technical artifacts we validated total mRNA
levels for two genes from each subset. The differences in regulation of gene
expression were not dependent on codon usage which has been described before in
a different context (Lorent et al., 2019). However, overall uncoupled mRNAs had
shorter 3’ UTRs with a higher GC content and were depleted for HuR binding
sites. Notably, there were no strong differences in 5’ UTR characteristics between
these subsets.
The depletion of HuR binding sites in the 3’ UTRs of the uncoupled subset
prompted us to investigate mRNA stability differences. Using a time series
experiment under actinomycin D treatment to block transcription quantified using
nanoString, we found significant longer mRNA half lifes for the uncoupled subset
as compared to the reversed subset. Based on these data, we hypothesised that
there are different underlying mechanisms that regulate gene expression under
conditions where mRNA translation is dampened between these subsets in MCF7
cells. Under this hypothesis: On one hand, the reversed subset could be regulated
through mRNA stability. Therefore, when translation is inhibited total RNA
levels would be reduced by destabilisation of the mRNA. On the other hand
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the uncoupled subset cannot be de-stabilised and has longer half lives than the
reversed subset. Therefore, their increased total mRNAs levels require to be
translationally offset under conditions when mRNA translation is inhibited.
The involvement of HuR in this cannot be fully supported with our current data
as the analysis only supports a correlation between the occurrence of HuR binding
sites and the 3’ UTRs of the reversed subset. The effect on stability could be due
to other trans acting factors, e.g. miRNAs and other RBPs (Valinezhad Orang
et al., 2014). A way to increase confidence is to investigate HuRs involvement
experimentally, e.g. we could use a small interfering (siRNA) to silence HuR and
measure total mRNA levels of the reversed and uncoupled mRNAs previously
validated by qPCR. If HuR is involved, we would expect that the reversed mRNAs
retain higher total mRNA levels under the condition where mTOR is inhibited
during insulin stimulation in MCF7 cells as compared to control. Furthermore,
while the differences in total mRNA levels between the insulin and the insulin
and torin1 treated conditions in the RNAseq data imply a treatment effect on the
mRNA stability we did not observe this in the time chase experiment quantified
by nanoString. This raises the question whether the transcription block induced
by actinomycin D could influence the regulation of mRNA stability between
treatments. We could address this by including actinomycin D in the siHuR
experiment and see if effects thereof differ or setup an experiment independent of
siHuR. Presence of an effect of actinomycin D on mRNA stability could indicate
a cross-talk between transcription and regulation of mRNA stability.
Since the translational offsetting identified herein was only observed in insulin
treated cancer cells, we wondered whether this is only specific to this system.
It has been shown that cancer cells can become more “stem-cell-like” (Jewer et
al., 2020; Quail et al., 2012; Wahl et al., 2017). Therefore, we reasoned that
a system where we study gene expression of stem cells could give some insight
whether cancer cells obtained stem cell features that normal epithelial cells do
not have. Furthermore, we wanted to investigate whether other means of mTOR
inactivation, e.g. hypoxia, would lead to similar effects on gene expression. To
assess these aspects we cultured H9 stem cells in medium with insulin present
in normoxia and hypoxia. This experimental setup differs to that of MCF7 and
HMEC cells as these were serum starved (i.e. no insulin in medium) prior to
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induction with insulin.
Studying this system in H9, we observed changes for all three modes for regulation
of gene expression. Most notably, we observed a large fraction of translationally
buffered mRNAs with similar 3’ UTR characteristics to that of the uncoupled
subset in MCF7 cells. Using publicly available data on mRNA stability we saw
that the translationally buffered mRNA were overall more stable as compared
to their background. Furthermore, visualising the reversed and uncoupled subset
identified in MCF7 in the H9 data we observe differences in their regulation of total
mRNA levels, indicating that these subset underlie different modes of regulation
even across these two models. Furthermore, these data argue for that translational
buffering observed in insulin treated MCF7 cells during mTOR inhibition is not
limited to that system but can also occur under more other conditions where
mTOR is inhibited.
Here, we present an unprecedented and comprehensive investigation of the effects
on insulin on gene expression in cancer cells and non- transformed epithelial
cells across multiple steps of the gene expression pathway. Our results indicate
that cancer cells have acquired an increased sensitivity to insulin signalling as
compared to non-transformed epithelial cells that is largely dependent on mTOR
in both cell types. Furthermore, we observed that cancer cells have the ability to
translationally buffer mRNAs which is a feature they share with stem cells.
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4. Conclusions
Cancer is a vastly heterogeneous disease that is characterised by uncontrollable
growth and proliferation as well as dysregulated metabolism that can evade
therapy through acquiring resistance. mRNA translation is a common
denominator of these processes and it is therefore paramount to understand the
precise mechanisms by which mRNA translation is regulated to better formulate
therapeutic strategies against cancer.
This thesis provides an advance in methodology to analyse transcriptome-wide
changes translation efficiencies that can be applied to study cancer models.
Using this methodology in the context of pancreatic cancer we could propose a
possible new therapeutic strategy for this lethal disease where treatment options
are limited. Lastly, we explore the effects of insulin on gene expression in an
unprecedented study that highlighted an adapted insulin responsiveness of cancer
cells. Furthermore, we illuminate the ability of cancer cells to translationally
buffer genes which is a feature they share with stem cells and could therefore be
an acquired mechanism.
Taken together this thesis provides insight on gene expression in two different
cancer models that could potentially lead to clinical applications. While these
studies are a step forward, more research is needed to grasp the full extent of the
mechanisms involved in cancer.
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